“…Recently, the anti‐IL‐12p40 monoclonal antibody ( Ustekinumab ™) has demonstrated good clinical efficacy in a group of UC patients resistant to anti‐TNF therapy (Sandborn et al, ) demonstrating that blocking the communication between CD11c + and T‐cells can result in a decrease in the activity of the IL‐12/23 pro‐inflammatory pathway (Fitzpatrick, ). Among various intracellular pathways that activate CD11c + cell functions, NF‐κB pathway regulates IL‐12/23 production (Kaiko et al, ; Rescigno, Martino, Sutherland, Gold, & Ricciardi‐Castagnoli, ; Tas et al, ), and in active UC, activation of NF‐κB is increased in lamina propria mononuclear cells; therefore, inhibition of the NF‐κB pathway has been proposed as a therapeutic strategy (Eissa, Hussein, Kermarrec, Elgazzar, et al, ; Eissa & Ghia, ; Eissa, Hussein, Hendy, Bernstein, & Ghia, ).…”